Echo IQ Limited (ASX:EIQ), an AI and medical technology company focused on cardiology, has recorded one of the largest share price gains among ASX-listed technology companies over the past year. Echo IQ Limited (ASX:EIQ) shares were priced at $0.545, down 1.80% in today’s session, and are up 211.43% over the past year. On 17 September 2026 the company provided an update on its US Food and Drug Administration (FDA) application for EchoSolv HF, following a Not Substantially Equivalent (NSE) determination referenced in an earlier announcement dated 8 September 2026.

For context, the S&P/ASX 200 Info Tech [XIJ] (INDEXASX: XIJ) stood at 1,684.00, down 2.90% (−50.30 points) today as of 6 Oct, and is down 42.73% over the past year. Meanwhile, the S&P/ASX 200 stood at 8,735.70, up 0.57% (+49.30 points) today, and is down 2.74% over the past year.

Business Model and Operational Footprint

Echo IQ develops proprietary software to improve clinical decision-making in cardiology. Its flagship product, EchoSolv AS, is FDA-cleared for use as a clinical decision support aid in detecting severe aortic stenosis. EchoSolv HF, a heart failure product, is the subject of the pending 510(k) application. The company is headquartered in Sydney, Australia, with US operations based in Greenville, Delaware.

Echo IQ operates through partnerships with healthcare and imaging technology organisations. The announcement references strategic partner agreements with Advara HeartCare, Mayo Clinic and Pro Medicus Limited. A further commercial arrangement with Pro Medicus, including a convertible note, is referenced in the forward-looking statements, with an additional A$10 million Investment Tranche stated to be conditional on FDA clearance of EchoSolv HF.

Sector Dynamics

Medical device software that uses AI is regulated by the FDA, and the 510(k) pathway requires a manufacturer to show that a device is substantially equivalent to a legally marketed device. Clinical validation, including statistical analysis, is a central part of such submissions, and outcomes affect commercial timing for companies without other Revenue sources.

Reimbursement is also a variable. The announcement refers to the US Centers for Medicare and Medicaid Services (CMS) Calendar Year 2027 proposed rule and a proposed interim Software as a Medical Service payment methodology as items relevant to EchoSolv. Within ASX technology, Echo IQ’s 211.43% one-year gain is the largest of the group, compared with a 42.73% decline for the S&P/ASX 200 Info Tech index. Today the shares are down 1.80% at $0.545.

FDA Update Release

The company reports that it received an NSE determination from the FDA on its initial EchoSolv HF 510(k) application. Echo IQ states that it has started work with regulatory consultants and legal counsel and believes there is a clear path to clearance, which could potentially be achieved over the coming quarters.

According to Echo IQ’s assessment, the matters cited by the FDA are limited to aspects of the statistical analysis supporting clinical validation, and its review did not identify concerns relating to the underlying technology or core functionality of the device. The company says it will keep working with the FDA to address all matters cited.

Three pathways are under assessment: an administrative appeal of the NSE determination, review through the FDA Ombudsman, or a new 510(k) submission. An administrative appeal does not have strictly defined timelines and, in certain circumstances, may take less than 90 days. It could result in the determination being overturned, the FDA reopening its review, or a request for resubmission with clarity on matters to resolve. The Ombudsman can provide procedural review support, and a resubmission could be undertaken over the coming quarters. Echo IQ states that there has been no material impact on its strategic partner agreements.

Growth Catalysts and Critical Operating Risks

Growth catalysts identified include potential FDA clearance of EchoSolv HF, the A$10 million tranche linked to clearance, the existing clearance of EchoSolv AS, partner relationships and possible reimbursement frameworks under CMS proposals.

Operating risks include the NSE determination itself, uncertain timelines for any appeal, Ombudsman review or resubmission, the possibility that the FDA may request additional validation, and the dependence of further funding on regulatory outcomes. The company’s statements that clearance “could” be achieved over coming quarters are forward-looking and not guaranteed. The forward-looking statements also cite risks relating to the terms of the convertible note, completion of an institutional placement, finalisation of CMS rules and conversion of the commercial pipeline into executed contracts.

Where Things Stand

Echo IQ is assessing pathways to FDA clearance for EchoSolv HF after the NSE determination, while its shares remain well above levels of a year ago. Future reference points include the company’s choice of regulatory pathway, any FDA response and further ASX updates.